Switch theme
Sign up to access all valuation multiples
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
2000
3.9K+
LTM Revenue $2.3B
LTM EBITDA $502M
$23.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Insulet has a last 12-month revenue (LTM) of $2.3B and a last 12-month EBITDA of $502M.
In the most recent fiscal year, Insulet achieved revenue of $2.1B and an EBITDA of $424M.
Insulet expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Insulet valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.3B | XXX | $2.1B | XXX | XXX | XXX |
| Gross Profit | $1.6B | XXX | $1.4B | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $502M | XXX | $424M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $355M | XXX | $309M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $271M | XXX | $418M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $439M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Insulet's stock price is $325.
Insulet has current market cap of $22.9B, and EV of $23.3B.
See Insulet trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23.3B | $22.9B | XXX | XXX | XXX | XXX | $3.71 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Insulet has market cap of $22.9B and EV of $23.3B.
Insulet's trades at 11.2x EV/Revenue multiple, and 55.0x EV/EBITDA.
Equity research analysts estimate Insulet's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Insulet has a P/E ratio of 84.5x.
See valuation multiples for Insulet and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $22.9B | XXX | $22.9B | XXX | XXX | XXX |
| EV (current) | $23.3B | XXX | $23.3B | XXX | XXX | XXX |
| EV/Revenue | 10.3x | XXX | 11.2x | XXX | XXX | XXX |
| EV/EBITDA | 46.4x | XXX | 55.0x | XXX | XXX | XXX |
| EV/EBIT | 65.7x | XXX | 75.4x | XXX | XXX | XXX |
| EV/Gross Profit | 14.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 84.5x | XXX | 54.7x | XXX | XXX | XXX |
| EV/FCF | 75.1x | XXX | 78.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInsulet's last 12 month revenue growth is 20%
Insulet's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Insulet's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Insulet's rule of X is 72% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Insulet and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | 33% | XXX | XXX | XXX |
| Rule of 40 | 39% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 72% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Insulet acquired XXX companies to date.
Last acquisition by Insulet was XXXXXXXX, XXXXX XXXXX XXXXXX . Insulet acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Insulet founded? | Insulet was founded in 2000. |
| Where is Insulet headquartered? | Insulet is headquartered in United States of America. |
| How many employees does Insulet have? | As of today, Insulet has 3.9K+ employees. |
| Who is the CEO of Insulet? | Insulet's CEO is Ms. Ashley A. McEvoy. |
| Is Insulet publicy listed? | Yes, Insulet is a public company listed on NAS. |
| What is the stock symbol of Insulet? | Insulet trades under PODD ticker. |
| When did Insulet go public? | Insulet went public in 2007. |
| Who are competitors of Insulet? | Similar companies to Insulet include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Insulet? | Insulet's current market cap is $22.9B |
| What is the current revenue of Insulet? | Insulet's last 12 months revenue is $2.3B. |
| What is the current revenue growth of Insulet? | Insulet revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Insulet? | Current revenue multiple of Insulet is 10.3x. |
| Is Insulet profitable? | Yes, Insulet is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Insulet? | Insulet's last 12 months EBITDA is $502M. |
| What is Insulet's EBITDA margin? | Insulet's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Insulet? | Current EBITDA multiple of Insulet is 46.4x. |
| What is the current FCF of Insulet? | Insulet's last 12 months FCF is $310M. |
| What is Insulet's FCF margin? | Insulet's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Insulet? | Current FCF multiple of Insulet is 75.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
